Are we ready for positron emission tomography/computed tomography-based target volume definition in lymphoma radiation therapy?

International Journal of Radiation Oncology Biology Physics

Volumn 85, Issue 1, 2013, Pages 14-20

  Yeoh, Kheng Wei ^a   Mikhaeel, N George ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPUTERIZED TOMOGRAPHY; DECISION MAKING; ONCOLOGY; POSITRONS; RADIOTHERAPY;

CLINICAL MANAGEMENT; FLUORINE-18; FLUORODEOXYGLUCOSE; PLANNING PROCESS; POSITRON EMISSION TOMOGRAPHY (PET); POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHIES; RADIATION THERAPY TREATMENT; TARGET VOLUMES;

POSITRON EMISSION TOMOGRAPHY;

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; PREDNISOLONE; VINBLASTINE; VINCRISTINE;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LYMPH NODE; LYMPHOMA; MARGINAL ZONE LYMPHOMA; MEDICAL DECISION MAKING; NODAL MARGINAL ZONE LYMPHOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPLENIC MARGINAL ZONE LYMPHOMA; TREATMENT PLANNING;

EID: 84871381659     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2012.02.023     Document Type: Review

References (64)

1. H.S. Kaplan The radical radiotherapy of regionally localized Hodgkin's disease Radiology 78 1962 553 561
2. M.S. Kaminski, C.N. Coleman, and T.V. Colby Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiation therapy Ann Intern Med 104 1986 747 756 (Pubitemid 16115036)
3. M. Gospodarowicz, R. Tsang, and D. Hodgson Lymphomas P. Hoskin, Oxford Textbook of Radiation Oncology 2005 Oxford University Press Oxford
4. H. Kaplan Survival and relapse rates in Hodgkin's disease: Stanford experience, 1961-71 Natl Cancer Inst Monogr 36 1973 487 496
5. C. Ferme, H. Eghbali, and H. Jacobus Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease N Engl J Med 357 2007 1916 1927 (Pubitemid 350074687)
6. A. Engert, J. Franklin, and H.T. Eich Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial J Clin Oncol 25 2007 3495 3502 (Pubitemid 47310889)
7. H. Eghbali, P. Brice, and G.-Y. Creemers Comparison of supradiaphragmatic clinical stages (CS) I-II Hodgkin's lymphoma (HL): preliminary results of the EORTC-GELA H9-F trial Blood 106 2005 814a
8. J.B. Nachman, R. Sposto, and P. Herzog Randomized comparison of low-dose involved-field radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy J Clin Oncol 20 2002 3765 3771
9. R.M. Meyer, M.K. Gospodarowicz, and J.M. Connors Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group J Clin Oncol 23 2005 4634 4642 (Pubitemid 46237440)
10. D.J. Straus, C.S. Portlock, and J. Qin Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease Blood 104 2004 3483 3489 (Pubitemid 39564416)
11. C. Herbst, F.A. Rehan, and C. Brillant Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: a systematic review Haematologica 95 2010 494 500
12. S.J. Horning, E. Weller, and K. Kim Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484 J Clin Oncol 22 2004 3032 3038 (Pubitemid 41103714)
13. T.P. Miller, S. Dahlberg, and J.R. Cassady Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate and high-grade non-Hodgkin's lymphoma N Engl J Med 339 1998 21 26 (Pubitemid 28304493)
14. T.N. Shenkier, N. Voss, and R. Fairey Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency J Clin Oncol 20 2002 194 204
15. J. Phan, A. Mazloom, and L. Jeffrey Medeiros Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy J Clin Oncol 28 2010 4170 4176
16. A.D. Zelenetz, A.D. Abramson, and R.H. Advani NCCN practice guidelines in oncology: non-Hodgkin's lymphomas J Natl Compr Canc Netw 8 2010 288 334
17. G. Bonadonna, V. Bonfante, and S. Viviani ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results J Clin Oncol 22 2004 2835 2841 (Pubitemid 41079901)
18. A. Engert, P. Schiller, and A. Josting Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavourable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group J Clin Oncol 21 2003 3601 3608 (Pubitemid 46594052)
19. E.M. Noordijk, P. Carde, and N. Dupouy Combined modality therapy for clinical stage I or II Hodgkin's lymphoma: long term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials J Clin Oncol 24 2006 3128 3156
20. J. Yahalom, and P. Mauch The involved field is back: issues in delineating the radiation field in Hodgkin's disease Ann Oncol 13 suppl 1 2002 79 83 (Pubitemid 34567406)
21. U. Rühl, M. Albrecht, and K. Dieckmann Response-adapted radiotherapy in the treatment of pediatric Hodgkin's disease: an interim report at 5 years of the German GPOH-HD 95 trial Int J Radiat Oncol Biol Phys 51 2001 1209 1218 (Pubitemid 33116313)
22. P. Diez, P.J. Hoskin, and E.G. Aird Treatment planning and delivery of involved field radiotherapy in advanced Hodgkin's disease: results from a questionnaire-based audit for the UK Stanford V regimen vs ABVD clinical trial quality assurance programme (ISRCTN 64141244) Br J Radiol 80 2007 816 821 (Pubitemid 350205520)
23. J. Yahalom Transformation in the use of radiation therapy of Hodgkin lymphoma: new concepts and indications lead to modern field design and are assisted by PET imaging and intensity modulated radiation therapy (IMRT) Eur J Haematol 75 suppl 66 2005 90 97 (Pubitemid 40873984)
24. T. Girinsky, R. van der Maazen, and L. Specht Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines Radiother Oncol 79 2006 270 277 (Pubitemid 44109907)
25. M. Shahidi, N. Kamangari, and S. Ashley Site of relapse after chemotherapy alone in stage I and II Hodgkin's disease Radiother Oncol 78 2006 1 5 (Pubitemid 43131028)
26. B.A. Campbell, N. Voss, and T. Pickles Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size J Clin Oncol 26 2008 5170 5174
27. M. Dreyling Newly diagnosed and relapsed follicular lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up Ann Oncol 20 suppl 4 2009 iv119 iv120
28. R.T. Hoppe, F.H. Advani, and W.Z. Ai Hodgkin lymphoma J Natl Compr Canc Netw 9 2011 1020 1058
29. B.A. Campbell, N. Voss, and R. Woods Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy Cancer 116 2010 3797 3806
30. Y.S. Jhanwar, and D.J. Straus The role of PET in lymphoma J Nucl Med 47 2006 1326 1334 (Pubitemid 47544887)
31. M. Allen-Auerbach, A. Quon, and W.A. Weber Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma Mol Imaging Biol 6 2004 411 416 (Pubitemid 39618921)
32. T. Girinsky, M. Ghalibafian, and G. Bonniaud Is FDG-PET scan in patients with early-stage Hodgkin lymphoma of any value in the implementation of the involved-node radiotherapy concept and dose painting? Radiother Oncol 85 2007 178 186 (Pubitemid 350160993)
33. N. Tsukamoto, M. Kojima, and M. Hasegawa The usefulness of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) and a comparison of 18F-FDG-PET with gallium scintigraphy in the evaluation of lymphoma Cancer 110 2007 652 659
34. D.A. Podoloff, R.H. Advani, and C. Allred NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer J Natl Comp Canc Netw 5 suppl 1 2007 S1 S22
35. A. Wirth, J.F. Seymour, and R.J. Hicks Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma Am J Med 11 2002 262 268 (Pubitemid 34219438)
36. M. Meignan, A. Gallamini, and C. Haioun Report on the First International Workshop on interim-PET scan in lymphoma Leuk Lymphoma 50 2009 1257 1260
37. B.D. Cheson, B. Pfistner, and M.E. Juweid Revised response criteria for malignant lymphoma J Clin Oncol 25 2007 579 586 (Pubitemid 350002966)
38. M.E. Juweid, S. Stroobants, and O.S. Hoekstra Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma J Clin Oncol 25 2007 571 578 (Pubitemid 350002965)
39. N.G. Mikhaeel Use of FDG-PET to monitor response to chemotherapy and radiotherapy in patients with lymphomas Eur J Nucl Med Mol Imaging 33 suppl 1 2006 22 26
40. National Institutes of Health. PET scan in planning treatment in patients undergoing combination chemotherapy for stage IA or stage IIA Hodgkin lymphoma (a randomised phase III trial to determine the role of FDG-PET imaging in clinical stages IA/IIA Hodgkin's disease). Available at: http://www. clinicaltrials.gov/ct2/show/NCT00943423. Accessed December 28, 2011.
41. National Institutes of Health. HD16 for early stage Hodgkin lymphoma (HD16 for early stages-treatment optimization trial in the first-line treatment of early stage Hodgkin lymphoma;treatment stratification by means of FDG-PET). Available at: http://www.clinicaltrials.gov/ct2/show/NCT00736320. Accessed December 28, 2011.
42. National Institutes of Health. Fludeoxyglucose F 18 PET scan-guided therapy or standard therapy in treating patients with previously untreated stage I or stage II Hodgkin's lymphoma (the H10 EORTC/GELA/IIL randomized intergroup trial on early FDG-PET scan guided treatment adaptation versus standard combined modality treatment in patients with supradiaphragmatic stage I/II Hodgkin's lymphoma). Available at: http://www.clinicaltrials.gov/ct2/show/NCT00433433. Accessed December 28, 2011.
43. National Institutes of Health. Chemotherapy based on positron emission tomography scan in treating patients with stage I or stage II Hodgkin lymphoma. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01132807. Accessed December 28, 2011.
44. National Institutes of Health. Response-based therapy assessed by PET scan in treating patients with bulky stage I and stage II classical Hodgkin lymphoma. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01118026. Accessed December 28, 2011.
45. A. Engert, C. Kobe, and J. Markova Assessment of residual bulky tumor using FDG-PET in patients with advanced-stage Hodgkin's lymphoma after completion of chemotherapy: final report of the GHSG HD15 trial (abstr.). Presented at the Annual Meeting of the American Society of Hematology, December 2010 Blood (ASH Annual Meeting) 116 2010 764
46. C. Kobe, M. Dietlein, and J. Franklin Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma Blood 112 2008 3989 3994
47. M. Picardi, A. De Renzo, and F. Pane Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans Leuk Lymphoma 48 2007 1721 1727 (Pubitemid 47386707)
48. R. Advani, L. Maeda, and P. Lavori Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease J Clin Oncol 25 2007 3902 3907 (Pubitemid 47477267)
49. National Institutes of Health. High-dose chemotherapy and stem cell transplantation, in patients PET-2 positive, after 2 courses of ABVD and comparison of RT versus no RT in PET-2 negative patients (HD0801). Available at: http://www.clinicaltrials.gov/ct2/show/NCT00784537. Accessed December 28, 2011.
50. National Institutes of Health. Positron emission tomography (PET)-adapted chemotherapy in advanced Hodgkin Lymphoma (HL) (HD0607). Available at: http://www.clinicaltrials.gov/ct2/show/NCT00795613. Accessed December 28, 2011.
51. M. McManus, U. Nestle, and K.E. Rosenzweig Use of PET/CT for radiation therapy planning: IAEA expert report 2006-2007 Radiother Oncol 91 2009 85 94
52. D. Thorwarth, X. Geets, and Paiusco Physical radiotherapy treatment planning based on functional PET/CT data Radiother Oncol 96 2010 317 324
53. P.J. Slomka Software approach to merging molecular with anatomic information J Nucl Med 45 supp 1 2004 36s 45s
54. C.B. Caldwell, K. Mah, and M. Skinner Can PET provide the 3D extent of tumor motion for individualized internal target volumes? A phantom study of the limitations of CT and the promise of PET Int J Radiat Oncol Biol Phys 55 2003 1381 1393 (Pubitemid 36338307)
55. J.A. Lee Segmentation of positron emission tomography images: some recommendations for target delineation in radiation oncology Radiother Oncol 96 2010 302 307
56. J.A. Thie Understanding the standardized uptake value, its methods, and implications for usage J Nucl Med 45 2004 1431 1434 (Pubitemid 47618494)
57. M. Hatt, C. Cheze Le Rest, and P. Descourt Accurate automatic delineation of heterogeneous functional volumes in positron emission tomography for oncology applications Int J Radiat Oncol Biol Phys 77 2010 301 308
58. V. Bettinardi, M. Picchio, and N. Di Muzio Detection and compensation of organ/lesion motion using 4D-PET/CT respiratory gated acquisition techniques Radiother Oncol 96 2010 311 316
59. S.A. Nehmeh, Y.E. Erdi, and T. Pan Quantitation of respiratory motion during 4D-PET/CT acquisition Med Phys 31 2004 1333 1338 (Pubitemid 38808501)
60. H. Schoder, A. Noy, and M. Gonen Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma J Clin Oncol 23 2005 4643 4651 (Pubitemid 46224066)
61. Y.K. Lee, G. Cook, and M.A. Flower Addition of F-FDG-PET scans to radiotherapy planning of thoracic lymphoma Radiother Oncol 73 2004 277 283 (Pubitemid 39601074)
62. M. Hutchings, A. Loft, and M. Hansen Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma Eur J Haematatol 78 2007 206 212
63. S.A. Terzakis, M.A. Hunt, and A. Kowalski [18F]FDG-Positron emission tomography coregistration with computed tomography scans for radiation treatment planning of lymphoma and hematological malignancies Int J Radiat Oncol Biol Phys 81 2011 615 622
64. P. Pommier, S. Dussart, and T. Girinsky Impact of 18F-FDG-positron emission tomography on treatment strategy and radiotherapy planning for stage I-II Hodgkin disease: a prospective multicenter study Int J Radiat Oncol Biol Phys 79 2011 823 828